Cellectar Biosciences, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
James V. Caruso (President/CEO) and Chad J. Kolean (CFO) certified the June 30, 2026 quarterly report on August 13, 2026. Both officers affirmed that disclosure controls and internal financial reporting controls are effective, financial statements fairly present the company's condition and results, and no material weaknesses or fraud were identified. These are standard Sarbanes-Oxley attestation certifications required for all public companies.
Why this rating
Routine officer certifications required by law. No new material facts, transactions, or control failures disclosed. Boilerplate regulatory compliance filing.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.